News

Nov 26th 2018

Adrenomed closes €24 million financing led by Wellington Partners and HBM


Nov 06th 2018

Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"


More news

#ThinkBigger

 
 
 

Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.

 

Focus

Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams, deep domain knowledge.

Disruptive, innovative tech addressing high unmet medical needs in attractive markets.

 

Scope

Europe, special circumstances US, leader in Germany.

Seed to late-stage, private companies most of the time.

Ticket sizes from €1m up to €10m over life of investment.

 

Funds

Managing and investing out of funds WP III and WP IV.

More than €200m AUM dedicated to Life Sciences.

Investment Team with strong clinical, scientific and operational backgrounds.